array(57) { ["SERVER_SOFTWARE"]=> string(6) "Apache" ["REQUEST_URI"]=> string(109) "/instituto/idorensaio_clinico/estudo-tak24all-ponatinibe-3001-leucemia-linfoblastica-aguda-ph-primeira-linha/" ["PHP_PATH"]=> string(24) "/opt/bitnami/php/bin/php" ["FREETDSLOCALES"]=> string(0) "" ["FREETDSCONF"]=> string(0) "" ["OPENSSL_ENGINES"]=> string(31) "/opt/bitnami/common/lib/engines" ["OPENSSL_CONF"]=> string(39) "/opt/bitnami/common/openssl/openssl.cnf" ["SSL_CERT_FILE"]=> string(52) "/opt/bitnami/common/openssl/certs/curl-ca-bundle.crt" ["CURL_CA_BUNDLE"]=> string(52) "/opt/bitnami/common/openssl/certs/curl-ca-bundle.crt" ["LDAPCONF"]=> string(42) "/opt/bitnami/common/etc/openldap/ldap.conf" ["GS_LIB"]=> string(43) "/opt/bitnami/common/share/ghostscript/fonts" ["MAGICK_CODER_MODULE_PATH"]=> string(60) "/opt/bitnami/common/lib/ImageMagick-6.9.8/modules-Q16/coders" ["MAGICK_CONFIGURE_PATH"]=> string(73) "/opt/bitnami/common/lib/ImageMagick-6.9.8/config-Q16:/opt/bitnami/common/" ["MAGICK_HOME"]=> string(19) "/opt/bitnami/common" ["PATH"]=> string(260) "/opt/bitnami/apps/wordpress/bin:/opt/bitnami/varnish/bin:/opt/bitnami/sqlite/bin:/opt/bitnami/php/bin:/opt/bitnami/mysql/bin:/opt/bitnami/letsencrypt/:/opt/bitnami/apache2/bin:/opt/bitnami/common/bin:/usr/local/sbin:/usr/local/bin:/usr/sbin:/usr/bin:/sbin:/bin" ["USER"]=> string(6) "daemon" ["HOME"]=> string(9) "/usr/sbin" ["SCRIPT_NAME"]=> string(10) "/index.php" ["QUERY_STRING"]=> string(0) "" ["REQUEST_METHOD"]=> string(3) "GET" ["SERVER_PROTOCOL"]=> string(8) "HTTP/1.0" ["GATEWAY_INTERFACE"]=> string(7) "CGI/1.1" ["REDIRECT_URL"]=> string(109) "/instituto/idorensaio_clinico/estudo-tak24all-ponatinibe-3001-leucemia-linfoblastica-aguda-ph-primeira-linha/" ["REMOTE_PORT"]=> string(5) "52676" ["SCRIPT_FILENAME"]=> string(44) "/opt/bitnami/apps/wordpress/htdocs/index.php" ["SERVER_ADMIN"]=> string(15) "you@example.com" ["CONTEXT_DOCUMENT_ROOT"]=> string(34) "/opt/bitnami/apps/wordpress/htdocs" ["CONTEXT_PREFIX"]=> string(0) "" ["REQUEST_SCHEME"]=> string(4) "http" ["DOCUMENT_ROOT"]=> string(34) "/opt/bitnami/apps/wordpress/htdocs" ["REMOTE_ADDR"]=> string(13) "15.229.25.218" ["SERVER_PORT"]=> string(2) "80" ["SERVER_ADDR"]=> string(13) "172.26.13.183" ["SERVER_NAME"]=> string(13) "54.225.48.228" ["SERVER_SIGNATURE"]=> string(0) "" ["LD_LIBRARY_PATH"]=> string(410) "/opt/bitnami/sqlite/lib:/opt/bitnami/mysql/lib:/opt/bitnami/apache2/lib:/opt/bitnami/common/lib:/opt/bitnami/sqlite/lib:/opt/bitnami/mysql/lib:/opt/bitnami/apache2/lib:/opt/bitnami/common/lib:/opt/bitnami/varnish/lib:/opt/bitnami/varnish/lib/varnish:/opt/bitnami/varnish/lib/varnish/vmods:/opt/bitnami/sqlite/lib:/opt/bitnami/mysql/lib:/opt/bitnami/apache2/lib:/opt/bitnami/common/lib:/opt/bitnami/common/lib64" ["HTTP_ACCEPT_ENCODING"]=> string(7) "br,gzip" ["HTTP_VIA"]=> string(64) "1.1 e93e34046c3a3d7fb416e8e0d71d2ff2.cloudfront.net (CloudFront)" ["HTTP_X_AMZ_CF_ID"]=> string(56) "jbRk7z_Y6fS6sXLGLwym6ET-Dc-0JwXfsPqOlRCaBSfz2vfdiCzvjA==" ["HTTP_USER_AGENT"]=> string(17) "Amazon CloudFront" ["HTTP_X_AMZN_TRACE_ID"]=> string(40) "Root=1-62f071e6-0d48c7ed0f3cfc8d6a197c90" ["HTTP_X_FORWARDED_PORT"]=> string(2) "80" ["HTTP_CONNECTION"]=> string(5) "close" ["HTTP_X_FORWARDED_PROTO"]=> string(4) "http" ["HTTP_X_FORWARDED_FOR"]=> string(44) "44.197.230.180, 64.252.66.189, 10.247.45.143" ["HTTP_X_REAL_IP"]=> string(13) "10.247.45.143" ["HTTP_X_FORWARDED_HOST"]=> string(25) "www.rededorsaoluiz.com.br" ["HTTP_HOST"]=> string(13) "54.225.48.228" ["SCRIPT_URI"]=> string(129) "http://54.225.48.228/instituto/idorensaio_clinico/estudo-tak24all-ponatinibe-3001-leucemia-linfoblastica-aguda-ph-primeira-linha/" ["SCRIPT_URL"]=> string(109) "/instituto/idorensaio_clinico/estudo-tak24all-ponatinibe-3001-leucemia-linfoblastica-aguda-ph-primeira-linha/" ["REDIRECT_STATUS"]=> string(3) "200" ["REDIRECT_SCRIPT_URI"]=> string(129) "http://54.225.48.228/instituto/idorensaio_clinico/estudo-tak24all-ponatinibe-3001-leucemia-linfoblastica-aguda-ph-primeira-linha/" ["REDIRECT_SCRIPT_URL"]=> string(109) "/instituto/idorensaio_clinico/estudo-tak24all-ponatinibe-3001-leucemia-linfoblastica-aguda-ph-primeira-linha/" ["FCGI_ROLE"]=> string(9) "RESPONDER" ["PHP_SELF"]=> string(10) "/index.php" ["REQUEST_TIME_FLOAT"]=> float(1659924967.058) ["REQUEST_TIME"]=> int(1659924967) }

Estudo: TAK24ALL – Ponatinibe-3001 Leucemia linfoblástica aguda Ph(+) – primeira linha

Estudo: TAK24ALL – Ponatinibe-3001 Leucemia linfoblástica aguda Ph(+) – primeira linha

Resumo:

Estudo de Fase 3, Randomizado, Aberto, Multicêntrico Comparando o Ponatinibe Versus Imatinibe, Administrados em Combinação com Quimioterapia de Intensidade Reduzida, em Pacientes com Leucemia Linfoblástica Aguda Cromossomo Philadelphia Positivo (LLA Ph+) Recém-Diagnosticada

Local: Salvador
Áreas: Oncologia - Câncer Hematológicos
Investigador Principal: Dr. Marco Aurélio Salvino De Araújo

Resumo:

Salvador/BA
Instituição: IDOR Salvador
Informações: 11 94257-9076 (WhatsApp) / 11 2109-8804
E-mail:  nucleodecaptacao@idor.org

Mais Informações